$VXRT

Watson W. Mark purchased $7K of VXRT

Watson W. Mark purchased 10,000 shares of Vaxart, Inc. (VXRT) at $0.65 on 2026-05-22.

Original reporting
SEC EDGAR · Watson W. Mark
Published May 26, 2026, 4:00 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 6, 2026, 8:27 AM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefInsider activity
Primary signal
$VXRT
Bullish
low confidence
Mentioned
$VXRT
Relevance
4/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$VXRTBullishLow
01

Why it matters

The only new information is the director’s open-market purchase details and resulting share count; there is no accompanying guidance, trial update, or corporate action.

02

Market read

Traders may note the insider buy as a minor sentiment input, but it does not provide a new fundamental catalyst for VXRT.

03

What to watch

No 10b5-1 plan is noted, but the filing does not disclose intent, timing constraints, or whether other insiders are buying/selling around the same period.

Relevance 4/10Novelty 3/10Timing: filed 2026-05-26, transaction dated 2026-05-22

Background

The article is a Form 4 insider transaction disclosure for Vaxart, Inc. (VXRT).

Company-level read

Ticker impact

$VXRTBullishLow confidence
Context

Vaxart director Watson W. Mark bought 10,000 shares of VXRT at $0.6530/share, with holdings rising to 134,125 shares.

Expected impact

Likely limited near-term impact; any effect would be sentiment-driven and short-lived.

Evidence & confidence

Form 4 insider buys can signal confidence, but the disclosed size ($6,530) is relatively small and the filing provides no new company-specific operational or financial information.

Market effects

No clear read-through to the biotech sector from a single small insider purchase.

None.

None.

Counterpoint

The buy may reflect routine liquidity management or diversification rather than a strong forward-looking signal, especially given the modest dollar amount.

Key entities

  • Vaxart, Inc.

    Company whose insider transaction was disclosed on SEC Form 4.

  • Watson W. Mark

    Director who purchased 10,000 shares of VXRT at $0.6530/share.

Related articles

$VXRTMed

Vaxart, Inc. (VXRT): Results of Operations and Financial Condition

Vaxart, Inc. (VXRT) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 ex_1000406.htm EXHIBIT 99.1 ex_1000406.htm Exhibit 99.1 Vaxart Provides Business Update and Reports Second Quarter 2026 Financial Results Reported topline data from 400-person sentinel cohort of the Phase 2b COVID-19 trial; Topline data from 400-person sentinel safety c

$VXRTMed

Vaxart Announces Update to BARDA Funding Award to Reflect Current Scope of COVID-19 Oral Pill Vaccine Trial

Vaxart said it modified its BARDA funding contract via Advanced Technology International to match the current scope of its Phase 2b COVID-19 oral pill vaccine trial. Total available funding is now about $345 million, down ~$116 million after a BARDA partial termination reduced enrollment. The change releases ~$29 million to complete trial and exploratory analyses, enabling 12-month sentinel-cohort data in coming weeks and main-cohort data in 1H 2027.